Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
9,995 total articles
Rogerio Mendonca, president of the Equipment Group at Westinghouse Air Brake Technologies Corp (WAB), reported the sale of 3,500 company shares on February 20, 2026, in a Form 4 filing with the SEC. The two transactions totaled $924,719. The sale occurred while WAB shares were trading near a 52-week high and follows the company's recent fourth-quar…
A Royal Gold Inc. director sold just over $1.16 million of company stock on February 20, 2026, while the miner reported a fourth-quarter earnings shortfall but revenue that beat estimates. The shares have rallied sharply over the past year and are trading close to their 52-week peak, prompting investor attention as analysts weigh the latest financi…
Christine Zedelmayer, Senior Vice President and Chief Operating Officer of Equillium, sold 185,937 shares of common stock on February 19, 2026 under a pre-arranged 10b5-1 plan, receiving proceeds of $328,104. On the same day she exercised options to acquire 185,937 shares at exercise prices of $0.73 and $0.785 for a combined cost of $141,749. After…
Davis Barry E, a director at Kirby Corp (NYSE: KEX), sold 8,480 shares on February 19, 2026, for $1,089,764 while simultaneously exercising options to acquire the same number of shares. The stock sale occurred with Kirby trading near a 52-week high after a recent 30% rally. Kirby reported fourth-quarter 2025 earnings that beat per-share estimates b…
Amy D. Husted, Executive Vice President, General Counsel and Secretary of Kirby Corporation, sold 11,667 shares of KEX on February 20, 2026 for roughly $1.5 million and on the same day exercised options to buy 8,667 shares. The company reported a fourth-quarter 2025 EPS that beat estimates while missing on revenue, and named Tracy A. Embree to its …
Saba Capital Management, L.P. — identified as a ten-percent owner of the PIMCO Dynamic Income Strategy Fund (NYSE: PDX) — executed two block sales totaling 56,991 shares for about $1.16 million. The trades took place on February 19 and 20, 2026, at prices just above the fund's current market quote. After the disposals, Saba still retains an indirec…
Saba Capital Management, L.P., a roughly 10% holder of BlackRock ESG Capital Allocation Term Trust (ECAT), sold 75,148 shares of the trust's common stock on February 19 and 20, 2026. The transactions generated $1.13 million in proceeds at prices between $15.03 and $15.07 per share. After the sales, Saba Capital indirectly holds 23,669,210 shares of…
Ceribell, Inc. director Josef Parvizi sold 16,714 shares of common stock on February 19, 2026, for $338,792 under a pre-arranged Rule 10b5-1 trading plan. The stock has risen 68% over six months, and InvestingPro analysis indicates the company is trading above its Fair Value. Concurrent corporate developments include FDA Breakthrough Device Designa…
Murray Stahl, President and Co-Portfolio Manager of RENN Fund, Inc. (RCG), purchased 1,134 shares of the fund's common stock on February 20, 2026, at $2.84 per share, for a total outlay of $3,220. The shares were acquired across multiple transactions, some made directly and others through affiliated entities. At the time of the reporting, RCG trade…
Timothy P. Horne, a director at Watts Water Technologies Inc., sold 7,500 Class A Common Stock shares on February 20, 2026, for $2,475,300. The transaction occurred at prices between $330.00 and $330.90, compared with a listed share price of $323.10. Horne continues to hold 7,500 shares through a revocable trust. The company recently declared a qua…
Itron Inc. Senior Vice President and CFO Joan S. Hooper disposed of 15,293 shares on February 19, 2026, generating $1,522,242 to satisfy tax withholding tied to the vesting of a performance-based restricted stock unit award. The transaction leaves Hooper with 124,196 shares. Itron also announced a planned private offering of $600 million in convert…
Itron Inc.'s senior vice president for Networked Solutions, John F. Marcolini, sold 6,948 shares on February 19, 2026, generating $691,593 to satisfy tax withholding tied to vested performance-based restricted stock units. The transaction reduced his direct holdings to 26,912 shares. The move occurs as Itron reported fourth-quarter 2025 results tha…
Itron Inc. President and CEO Deitrich Thomas sold 56,095 shares on February 19, 2026, generating roughly $5.58 million. The disposition, executed at $99.5385 per share, was completed to cover tax withholding tied to the vesting of a performance-based restricted stock unit award. Following the sale, Deitrich holds 375,134 shares directly and 25,000 …
Itron Inc. Senior Vice President, Device Solutions, Patrick Justin K sold 4,930 shares on February 19, 2026 to satisfy tax withholding obligations tied to a performance-based restricted stock unit award. The transaction totaled $490,724 and leaves him with 34,344 shares. The sale accounts for less than 0.01% of Itron's $4.41 billion market capitali…
Laurie Ann Pulatie-Hahn, Itron's senior vice president of human resources, sold 3,755 shares on February 19, 2026, for $99.5385 per share, generating $373,767. The transaction was disclosed on a Form 4 filed with the Securities and Exchange Commission. Itron recently reported better-than-expected fourth-quarter 2025 results and announced a private …
Donald L. Reeves III, senior vice president of outcomes at Itron, sold 5,419 shares of the company on February 19, 2026, for $99.5385 per share, generating $539,399 in proceeds to satisfy tax withholding tied to a vesting performance-based restricted stock unit award. Itron recently reported fourth-quarter 2025 results above expectations, received …
Itron Inc. senior vice president and general counsel Christopher E. Ware sold 4,486 shares on February 19, 2026, at $99.5385 per share to satisfy tax withholding obligations associated with a performance-based restricted stock unit award. The transaction, disclosed in a Form 4 filing, left Ware with 31,806 shares. Separately, Itron reported fourth-…
City Holding Co's President and CEO, Charles R. Hageboeck, sold 1,275 shares of common stock on February 20, 2026, in two trades totaling $159,791. The company recently declared a quarterly cash dividend and drew a Neutral initiation from Piper Sandler, which set a $125 price target and published several return metrics for 2026. Hageboeck retains s…
Susan Street Whaley, Procter & Gamble's Chief Legal Officer and Secretary, sold 1,809 shares on February 19, 2026, in a transaction valued at $288,454. The move leaves her with a combination of directly and indirectly held shares and recent Restricted Stock Unit activity. Separately, Procter & Gamble reported fiscal second-quarter results that slig…
Ira P. Cohen, a director of Angel Oak Financial Strategies Income Term Trust (NYSE: FINS), acquired 379 shares of the trust's common stock on February 20, 2026, at $13.17 per share for a total outlay of $4,991. Separately, the board has announced that the annual shareholder meeting will be scheduled more than 30 days after the anniversary of last y…
Catherine A. Gridley, executive vice president and A&D Sector President at TTM Technologies Inc, sold 20,000 shares on February 20, 2026, for $2.12 million. The company reported fourth-quarter 2025 results that beat analyst expectations on both non-GAAP EPS and net sales, yet the stock fell in aftermarket trading. InvestingPro valuation metrics cit…
Peter J. Wilkinson, Labcorp's SVP and Chief Accounting Officer, sold 666 shares on February 19, 2026, for $277.94 per share, totaling $185,108. The transaction was carried out under a Rule 10b5-1 plan. Labcorp's stock trades at $282.67, up 12.67% year-to-date and cited as undervalued by InvestingPro. The company reported a Q4 2025 EPS beat alongsid…
Insulet Corp President and CEO Ashley McEvoy purchased 4,300 shares of common stock on February 20, 2026, for roughly $1.03 million, according to a Form 4 filing. The transaction occurred as the shares trade near a 52-week low. The company reported robust fourth-quarter 2025 revenue growth that beat several estimates, though earnings per share slig…
Director Raymond Debbane purchased 150,000 shares of Lexicon Pharmaceuticals (NASDAQ: LXRX) in two transactions on February 19-20, 2026. The buying occurred as the stock has risen 107% over the past year and follows a financing package of roughly $100 million. The FDA has cleared Lexicon's pilavapadin to advance to two Phase 3, placebo-controlled, …
On February 19, 2026, CNX Resources director Bernard Lanigan Jr. sold 46,119 shares of common stock for roughly $1.87 million after exercising options to acquire the same number of shares. The stock has climbed sharply over the past six months and was trading near its 52-week high at the time of the sale. Separately, CNX reported fourth-quarter 202…
